Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT06937749Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mazdutide in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Innovent Biologics. Primary endpoint: MASH Resolution With no Worsening of Fibrosis at 60 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
mazdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06937749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937749.